# **BUY**

**Gulf Oil Lubricants** 

# Castrol sale could create positive sentiment for Indian lubes

mka

Oil & Gas 🕨 Company Update > June 04, 2025

The strategic review and potential sale by BP Plc of its lubricant arm, Castrol Ltd, marks a major global corporate development in the otherwise quiet lubricant sector. Financial investors view the space cautiously, given potential long-term EV risks, though this deal could improve market sentiment. BP management has cited strong interest in Castrol, with recent media reports naming marquee players like Saudi Aramco and Reliance Industries (RIL), besides several PE and investment firms as interested parties, valuing Castrol at USD8-10bn. At USD10bn, Castrol Ltd's implied market-cap/CY24 EBIT is 12x, while Castrol India's is at 14x. The Indian business accounts for ~20% of Castrol's global earnings and enjoys a healthier outlook than other countries. We believe a change in ownership of Castrol, which holds 51% stake in Castrol India (not rated), could trigger a mandatory open offer for the Indian entity. HPCL's lube carve out and monetization is another event (which is, albeit, progressing slowly) that is eagerly awaited. Nevertheless, we find Gulf Oil Lubricants India (GOLI)'s valuation attractive at 11x CY24 EBIT. Even Veedol (not rated), which is putting forward 2% promoter OFS, is trading at 14x. We reiterate BUY on GOLI, with TP of Rs1,800. A stable currency and oil price scenario, and expected decline in base oil costs could expand EBITDA margin to 14-16% compared with the current guidance of 12-14%.

## Castrol India accounts for ~20% of Castrol Ltd's earnings

Castrol Ltd has seen good interest, per BP management. Media has reported that Saudi Aramco, RIL, and some PE and investment firms are interested in Castrol, with bankers assigning it a value of USD8-10bn. We note that Aramco owns the global business of Valvoline, while RIL and BP have an existing strong partnership in India (RIL fuel outlets sell Castrol lubes as well). As per available public data, Castrol Ltd's CY24 EBIT was USD831mn, while Castrol India's was USD180mn (Indian business contributing 22% of total EBIT). While CY24 was strong for Castrol Ltd at 14% EBIT growth vs Castrol India's at 7%, CY19-24 CAGR was -8% for Castrol and +2% for Castrol India, highlighting India as the more attractive market. We believe margins from the India business also exceed global margins by ~5ppt.

# HPCL lube carve-out, Veedol promoter offer are other corporate events

The Indian lubricant sector has seen a couple of more events like HPCL carving out its lube business to unlock value and Veedol's co-promoter Andrew Yule putting forward 2% OFS. HPCL's process is moving slower than expected, albeit is under way. Similarly, Veedol's OFS-supposed to take place last week-has hit a technical snag, according to media reports, and has been withdrawn, although it could be revived. We believe these transactions could also firm up valuation and generate positive sentiment for the sector. GOLI remains attractive valuation-wise. We value it at ~20x target PER.

Gulf Oil Lubricants: Financial Snapshot (Standalone)						
Y/E March (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E	
Revenue	32,841	35,544	38,346	41,292	44,449	
EBITDA	4,194	4,701	5,196	5,782	6,443	
Adj. PAT	3,081	3,533	4,023	4,560	5,147	
Adj. EPS (Rs)	62.7	71.7	81.6	92.5	104.4	
EBITDA margin (%)	12.8	13.2	13.6	14.0	14.5	
EBITDA growth (%)	22.3	12.1	10.5	11.3	11.4	
Adj. EPS growth (%)	32.2	14.4	13.9	13.4	12.9	
RoE (%)	24.9	26.3	26.2	27.1	27.8	
RoIC (%)	36.3	44.5	50.9	54.0	57.7	
P/E (x)	18.6	15.9	14.3	12.6	11.2	
EV/EBITDA (x)	13.0	11.1	9.9	8.7	7.6	
P/B (x)	4.4	3.9	3.6	3.3	3.0	
FCFF yield (%)	6.0	7.5	5.6	6.7	7.7	

Source: Company, Emkay Research

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

sabri.hazarika@emkavalobal.com

Sabri Hazarika

+91-22-66121282

Arya Patel arya.patel@emkayglobal.com +91-22-66121285

Target Price - 12M Mar-26 Change in TP (%) Current Reco. BUY Previous Reco. BUY Upside/(Downside) (%) 54.2

CMP (Rs): 1,167 | TP (Rs): 1,800

#### Stock Data GOLI IN 52-week High (Rs) 1.514

52-week Low (Rs)	849
Shares outstanding (mn)	49.3
Market-cap (Rs bn)	58
Market-cap (USD mn)	670
Net-debt, FY26E (Rs mn)	(6,622.4)
ADTV-3M (mn shares)	0
ADTV-3M (Rs mn)	163.8
ADTV-3M (USD mn)	1.9
Free float (%)	27.0
Nifty-50	24,620.2
INR/USD	85.9

## Shareholding, Mar-25

Promoters (%)	67.1
FPIs/MFs (%)	7.5/9.5

Price Performance						
(%)	1M	3M	12M			
Absolute	(1.9)	4.8	32.6			
Rel. to Nifty	(3.0)	(6.0)	17.9			

#### 1-Year share price trend (Rs)



USD mn	CY19	CY20	CY21	CY22	CY23	CY24	Q1CY25
Castrol Ltd (Global)							
EBITDA	1,402	979	1,187	853	897	1,007	284
D/A	144	161	150	153	167	176	46
EBIT	1,258	818	1,037	700	730	831	238
Growth		-35%	27%	-32%	4%	14%	15%
Сарех	229	173	173	235	262	227	37
Castrol India							
EBITDA	173	127	158	167	182	194	48
D/A	10	12	12	12	13	14	3
EBIT	163	115	147	156	169	180	45
Growth		-30%	28%	6%	8%	7%	-1%
Capex	11	9	11	15	14	12	4
Contribution of India							
EBITDA	12%	13%	13%	20%	20%	19%	17%
EBIT	13%	14%	14%	22%	23%	22%	19%
Capex	5%	5%	7%	6%	5%	5%	10%

Exhibit 2: GOLI's PER-ba	sed valuation (Ma	ar-27E)			
(Rs)	FY23	FY24	FY25	FY26E	FY27E
SA adjusted EPS	47.4	62.7	73.5	81.6	92.5
Target P/E (x)					19.5
ТР					1,800

Source: Company, Emkay Research

# **Gulf Oil Lubricants: Standalone Financials and Valuations**

Profit & Loss					
Y/E March (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
Revenue	32,841	35,544	38,346	41,292	44,449
Revenue growth (%)	9.5	8.2	7.9	7.7	7.6
EBITDA	4,194	4,701	5,196	5,782	6,443
EBITDA growth (%)	22.3	12.1	10.5	11.3	11.4
Depreciation & Amortization	468	459	479	515	571
EBIT	3,726	4,242	4,717	5,266	5,873
EBIT growth (%)	22.9	13.8	11.2	11.6	11.5
Other operating income	85	90	92	94	96
Other income	665	842	1,054	1,235	1,423
Financial expense	256	346	393	405	415
РВТ	4,135	4,738	5,378	6,096	6,881
Extraordinary items	0	120	0	0	0
Taxes	1,054	1,235	1,355	1,536	1,734
Minority interest	-	-	-	-	-
Income from JV/Associates	-	-	-	-	-
Reported PAT	3,081	3,622	4,023	4,560	5,147
PAT growth (%)	32.6	17.6	11.1	13.4	12.9
Adjusted PAT	3,081	3,533	4,023	4,560	5,147
Diluted EPS (Rs)	62.7	71.7	81.6	92.5	104.4
Diluted EPS growth (%)	32.2	14.4	13.9	13.4	12.9
DPS (Rs)	36.0	48.0	53.3	60.4	68.2
Dividend payout (%)	57.5	65.3	65.3	65.3	65.3
EBITDA margin (%)	12.8	13.2	13.6	14.0	14.5
EBIT margin (%)	11.3	11.9	12.3	12.8	13.2
Effective tax rate (%)	25.5	26.1	25.2	25.2	25.2
NOPLAT (pre-IndAS)	2,777	3,136	3,529	3,939	4,393
Shares outstanding (mn)	49	49	49	49	49

Balance Sheet					
Y/E March (Rs mn)	FY24	FY25	FY26E	FY27E	FY28
Share capital	98	99	99	99	99
Reserves & Surplus	12,849	14,544	15,939	17,521	19,30
Net worth	12,948	14,642	16,038	17,620	19,40
Minority interests	-	-	-	-	
Non-current liab. & prov.	160	119	89	58	2
Total debt	3,578	4,547	4,197	3,897	3,64
Total liabilities & equity	16,698	19,322	20,338	21,589	23,094
Net tangible fixed assets	2,468	2,750	2,817	2,747	2,67
Net intangible assets	36	0	0	0	
Net ROU assets	-	-	-	-	
Capital WIP	92	135	139	143	14
Goodwill	-	-	-	-	
Investments [JV/Associates]	1,950	1,923	1,961	2,001	2,04
Cash & equivalents	7,063	10,274	10,819	11,703	12,80
Current assets (ex-cash)	11,197	11,088	11,962	12,881	13,86
Current Liab. & Prov.	6,347	7,106	7,639	8,185	8,76
NWC (ex-cash)	4,850	3,982	4,323	4,696	5,103
Total assets	16,698	19,322	20,338	21,589	23,094
Net debt	(3,485)	(5,728)	(6,622)	(7,806)	(9,162
Capital employed	16,698	19,322	20,338	21,589	23,09
Invested capital	7,354	6,732	7,140	7,443	7,77
BVPS (Rs)	263.3	297.0	325.3	357.4	393.
Net Debt/Equity (x)	(0.3)	(0.4)	(0.4)	(0.4)	(0.5
Net Debt/EBITDA (x)	(0.8)	(1.2)	(1.3)	(1.4)	(1.4
Interest coverage (x)	17.1	14.7	14.7	16.1	17.
RoCE (%)	27.4	28.5	29.3	31.1	32.3

Source: Company, Emkay Research

Source: Company, Emkay Research

Cash flows					
Y/E March (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
PBT (ex-other income)	3,470	3,896	4,324	4,862	5,458
Others (non-cash items)	700	942	0	0	0
Taxes paid	(1,022)	(1,250)	(1,386)	(1,567)	(1,765)
Change in NWC	237	691	(361)	(394)	(430)
Operating cash flow	3,481	4,233	3,449	3,820	4,248
Capital expenditure	(210)	(339)	(550)	(450)	(500)
Acquisition of business	(999)	30	(38)	(39)	(40)
Interest & dividend income	633	810	1,054	1,235	1,423
Investing cash flow	(578)	494	466	745	883
Equity raised/(repaid)	53	52	0	0	0
Debt raised/(repaid)	(160)	689	(349)	(299)	(249)
Payment of lease liabilities	-	-	-	-	-
Interest paid	(264)	(305)	(393)	(405)	(415)
Dividend paid (incl tax)	(2,014)	(1,961)	(2,627)	(2,978)	(3,361)
Others	2	10	0	0	0
Financing cash flow	(2,382)	(1,515)	(3,370)	(3,682)	(4,026)
Net chg in Cash	521	3,211	545	883	1,106
OCF	3,481	4,233	3,449	3,820	4,248
Adj. OCF (w/o NWC chg.)	3,244	3,541	3,811	4,215	4,679
FCFF	3,272	3,894	2,899	3,370	3,748
FCFE	3,648	4,358	3,560	4,200	4,756
OCF/EBITDA (%)	83.0	90.0	66.4	66.1	65.9
FCFE/PAT (%)	118.4	120.3	88.5	92.1	92.4
FCFF/NOPLAT (%)	117.8	124.2	82.2	85.6	85.3

Source: Company, Emkay Research

Valuations and key Ratios Y/E March FY24 FY25 FY26E FY27E FY28E P/E (x) 18.6 15.9 14.3 11.2 12.6 P/CE(x) 16.2 14.1 12.8 11.3 10.1 P/B (x) 4.4 3.9 3.6 3.3 3.0 1.7 1.5 EV/Sales (x) 1.3 1.2 1.1 EV/EBITDA (x) 13.0 11.1 9.9 8.7 7.6 EV/EBIT(x) 14.6 12.3 10.9 9.5 8.3 EV/IC (x) 7.4 7.8 7.2 6.7 6.3 FCFF yield (%) 7.5 6.7 7.7 6.0 5.6 FCFE yield (%) 6,340.2 7.572.9 6,186.8 7.299.4 8,265.8 Dividend yield (%) 5.2 5.8 3.1 4.1 4.6 DuPont-RoE split Net profit margin (%) 9.4 10.2 10.5 11.0 11.6 Total asset turnover (x) 2.0 2.0 1.9 2.0 2.0 Assets/Equity (x) 1.3 1.3 1.2 1.3 1.2 RoE (%) 24.9 26.3 26.2 27.1 27.8 DuPont-RoIC NOPLAT margin (%) 9.9 8.5 8.8 9.2 9.5 IC turnover (x) 4.3 5.0 5.5 5.7 5.8 RoIC (%) 36.3 44.5 50.9 54.0 57.7 **Operating metrics** 40.9 Core NWC days 53.9 41.5 41.1 41.9 Total NWC days 41.1 41.5 53.9 40.9 41.9 Fixed asset turnover 8.0 8.0 7.6 7.5 7.4 Opex-to-revenue (%) 28.2 29.2 28.4 28.9 28.2

Source: Company, Emkay Research

This report is intended for Team White Margue Solutions (team.emkav@whitemarguesolutions.com) use and downloade


Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

# **RECOMMENDATION HISTORY - DETAILS**

Date	Closing Price (INR)	TP (INR)	Rating	Analyst
23-May-25	1,237	1,800	Buy	Harsh Maru
08-Feb-25	1,165	1,800	Buy	Harsh Maru
26-Nov-24	1,107	1,800	Buy	Harsh Maru
08-Nov-24	1,193	1,800	Buy	Harsh Maru
07-Aug-24	1,152	1,500	Buy	Harsh Maru
14-Jul-24	1,213	1,500	Buy	Harsh Maru
21-Jun-24	1,013	1,350	Buy	Harsh Maru
22-May-24	1,046	1,350	Buy	Sabri Hazarika
09-Apr-24	1,096	1,350	Buy	Sabri Hazarika
06-Feb-24	898	1,200	Buy	Sabri Hazarika
30-Nov-23	697	750	Add	Sabri Hazarika
26-Oct-23	573	750	Buy	Sabri Hazarika
09-Oct-23	526	730	Buy	Sabri Hazarika
06-Aug-23	570	730	Buy	Sabri Hazarika
27-Jul-23	492	650	Buy	Sabri Hazarika

# **RECOMMENDATION HISTORY - TREND**





Source: Company, Emkay Research

# GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to be as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayqlobal.com.

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit www.emkayglobal.com to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL . All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company.

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

**Disclaimer for U.S. persons only:** Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

This report is intended for Team White Marque Solutions (team.emkav@whitemarquesolutions.com) use and downloaded

## **RESTRICTIONS ON DISTRIBUTION**

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

## ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons1 may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests2 in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

<sup>1</sup> An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

<sup>2</sup> Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

# COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

- 1. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative's may have Financial Interest/proprietary positions in the securities recommended in this report as of June 04, 2025
- 2. EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report

## Disclosure of previous investment recommendation produced:

- 3. EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's may have material conflict of interest in the securities recommended in this report as of June 04, 2025
- EGFSL, its affiliates and Research Analyst or his/her associate/relative's may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the June 04, 2025
- 6. EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months.
- 7. EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- 8. EGFSL, its affiliates and/or and Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

## **Emkay Rating Distribution**

Ratings	Expected Return within the next 12-18 months.
BUY	>15% upside
ADD	5-15% upside
REDUCE	5% upside to 15% downside
SELL	<15% downside

# Emkay Global Financial Services Ltd.

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com

## OTHER DISCLAIMERS AND DISCLOSURES:

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) -:

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. . Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit www.emkayglobal.com to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. EGFSL or its associates may have received compensation from the subject company in the past twelve months. Subject Company may have been client of EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates may have co-managed public offering of securities for the subject company in the past twelve months.